Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma who received immunotherapy beyond two years, according to results from a phase II clinical trial presented at #AACR26 by Alice P. Chen, MD.
https://
brnw.ch/21x1Lnf
@theNCI